Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Waratah Pharmaceuticals Inc | 14 |
| 2 | Poseidon Medical Inc | 13 |
| 3 | Medtronic Inc | 12 |
| 4 | Galapagos NV | 9 |
| 5 | Zurich Universität | 7 |
| 6 | 9 Meters Biopharma Inc | 5 |
| 7 | Chugai Pharmaceutical Co Ltd | 5 |
| 8 | Sierra Oncology Inc | 5 |
| 9 | Transition Therapeutics Inc | 5 |
| 10 | Beth Israel Deaconess Medical Center | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 157 |
| 2 | A61K | Medicinal preparations | 143 |
| 3 | C07K | Peptides | 41 |
| 4 | C12N | Microorganisms, enzymes | 39 |
| 5 | G01N | Investigating / analysing materials | 39 |
| 6 | C07D | Heterocyclic compounds | 33 |
| 7 | A61L | Sterilising / disinfecting materials | 20 |
| 8 | A61M | Devices for introducing media into the body | 16 |
| 9 | C12Q | Measuring/testing involving enzymes | 16 |
| 10 | A61F | 15 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Sphingolipid Metabolism and Signaling | 3 |
| 2 | Drug Transport and Resistance Mechanisms | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Jacek Bielawski | Medical University of South Carolina | 6 |
| 2 | Raghubir P. Sharma | University of Georgia | 6 |
| 3 | Lina M. Obeid | Ralph H. Johnson VA Medical Center | 5 |
| 4 | Yusuf A. Hannun | Medical University of South Carolina | 5 |
| 5 | Alfred H. Merrill | Georgia Institute of Technology | 4 |
| 6 | Besim Öğretmen | Medical University of South Carolina | 4 |
| 7 | Brett Garner | UNSW Sydney | 4 |
| 8 | Elias N. Glaros | Neuroscience Research Australia | 4 |
| 9 | Quanren He | University of Georgia | 4 |
| 10 | Charles E. Chalfant | Medical University of South Carolina | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Ceramide-mediated Macroautophagy Involves Inhibition of Protein Kinase B and Up-regulation of Beclin 1 | 2004 | 455 | Lipid Membrane Structure and Behavior |
| Ceramide is a cardiotoxin in lipotoxic cardiomyopathy | 2008 | 407 | Sphingolipid Metabolism and Signaling |
| De Novo Ceramide Regulates the Alternative Splicing of Caspase 9 and Bcl-x in A549 Lung Adenocarcinoma Cells | 2002 | 336 | Lipid Membrane Structure and Behavior |
| Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome | 2009 | 295 | Sphingolipid Metabolism and Signaling |
| Ceramide Synthase Inhibition by Fumonisin B1 Causes Accumulation of 1-Deoxysphinganine | 2008 | 237 | Polysaccharides and Plant Cell Walls |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of this compound?
Which organizations hold the most patents related to this compound?
What research topics are most associated with this compound?
Which author has published the most papers on this compound?
What patent classification areas dominate the intellectual property landscape?